Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line (1L) Pembrolizumab (pembro)  + Carboplatin (carbo) + Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

The standard-of-care (SOC) first-line treatment (1L) for R/M HNSCC consists of pembrolizumab (pembro)  + platinum + fluorouracil (5-fluorouracil). However, 5-fluorouracil is associated with potential administration complications and related toxicity, creating the need for alternative chemotherapy combinations. The global, prospective phase 4 KEYNOTE-B10 study (NCT04489888) evaluated pembro  + carboplatin (carbo) + paclitaxel (pacli) as 1L therapy for R/M HNSCC. Interim results of KEYNOTE-B10 showed promising antitumor activity for the initial 82 patients and manageable safety after a median follow-up of 8 months, suggesting that this 5-fluorouracil–free regimen could be a viabl e alternative for 1L R/M HNSCC.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Dzienis, J. Cundom, C.S. Fuentes, A. Spreafico, M.J. Nordlinger, A.V. Pastor, E. Alesi, A. Neki, A.S. Fung, I.P. Figueiredo Lima, P. Oppelt, G.F. da Cunha Junior, F.A. Franke, J. Tseng, A.J. Joshi, J. McCarthy, Y. Sidi, B. Gumuscu, N. Naicker, G. de Ca Tags: 3 Source Type: research